Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James William Rogers sold 22,529 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,117,663.69. Following the completion of the sale, the chief financial officer directly owned 132,337 shares in the company, valued at approximately $6,565,238.57. The trade was a 14.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
James William Rogers also recently made the following trade(s):
- On Wednesday, August 19th, James William Rogers sold 26,313 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00.
- On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.
Tempus AI Price Performance
TEM opened at $72.69 on Friday. The company’s 50 day simple moving average is $52.93 and its 200 day simple moving average is $51.36. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32. The stock has a market capitalization of $13.12 billion, a PE ratio of -50.48 and a beta of 3.58.
Institutional Trading of Tempus AI
Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Tempus AI by 5.3% during the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares during the period. GC Wealth Management RIA LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. raised its stake in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.
Tempus AI News Summary
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
- Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
- Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
- Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
- Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
- Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.
Analysts Set New Price Targets
TEM has been the topic of several research reports. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Lake Street Capital downgraded Tempus AI to a “hold” rating in a report on Monday, July 20th. Finally, Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus target price of $65.69.
Read Our Latest Analysis on Tempus AI
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Read More
- Five stocks we like better than Tempus AI
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
